- Home
- HLNE vs AXSM Comparison
HLNE vs AXSM Comparison
Compare HLNE & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLNE
- AXSM
- Stock Information
- Founded
- HLNE 1991
- AXSM 2012
- Country
- HLNE United States
- AXSM United States
- Employees
- HLNE N/A
- AXSM N/A
- Industry
- HLNE Investment Managers
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- HLNE Finance
- AXSM Health Care
- Exchange
- HLNE Nasdaq
- AXSM Nasdaq
- Market Cap
- HLNE 5.9B
- AXSM 5.1B
- IPO Year
- HLNE 2017
- AXSM 2015
- Fundamental
- Price
- HLNE $153.71
- AXSM $121.28
- Analyst Decision
- HLNE Hold
- AXSM Strong Buy
- Analyst Count
- HLNE 7
- AXSM 16
- Target Price
- HLNE $160.43
- AXSM $176.56
- AVG Volume (30 Days)
- HLNE 366.3K
- AXSM 562.3K
- Earning Date
- HLNE 08-05-2025
- AXSM 08-04-2025
- Dividend Yield
- HLNE 1.40%
- AXSM N/A
- EPS Growth
- HLNE 18.07
- AXSM N/A
- EPS
- HLNE 5.15
- AXSM N/A
- Revenue
- HLNE $692,190,000.00
- AXSM $495,033,000.00
- Revenue This Year
- HLNE $6.15
- AXSM $64.05
- Revenue Next Year
- HLNE $15.05
- AXSM $56.46
- P/E Ratio
- HLNE $29.98
- AXSM N/A
- Revenue Growth
- HLNE 10.66
- AXSM 69.83
- 52 Week Low
- HLNE $124.10
- AXSM $75.56
- 52 Week High
- HLNE $203.72
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- HLNE 50.72
- AXSM 70.77
- Support Level
- HLNE $152.67
- AXSM $115.99
- Resistance Level
- HLNE $155.80
- AXSM $123.59
- Average True Range (ATR)
- HLNE 3.83
- AXSM 3.29
- MACD
- HLNE -0.24
- AXSM 1.24
- Stochastic Oscillator
- HLNE 48.24
- AXSM 88.56
About HLNE Hamilton Lane Incorporated
Hamilton Lane Inc is a private market investment solutions provider in the United States. It works with its clients to conceive, structure, build out, manage and monitor portfolios of private markets funds and direct investments, and it helps them access a set of such investment opportunities around the world. The company offers a range of investment solutions across a range of private markets, including private equity, private credit, real estate, infrastructure, natural resources, growth equity, venture capital and impact. The company generate revenues mainly from management and advisory fees.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.